Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Deferred Revenue (2016 - 2018)

Neurocrine Biosciences filings provide 9 years of Current Deferred Revenue readings, the most recent being $731000.0 for Q1 2018.

  • On a quarterly basis, Current Deferred Revenue fell 79.42% to $731000.0 in Q1 2018 year-over-year; TTM through Mar 2018 was $731000.0, a 79.42% decrease, with the full-year FY2017 number at $731000.0, up 55.53% from a year prior.
  • Current Deferred Revenue hit $731000.0 in Q1 2018 for Neurocrine Biosciences, roughly flat from $731000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $10.2 million in Q1 2015 to a low of $52000.0 in Q2 2014.
  • Median Current Deferred Revenue over the past 5 years was $731000.0 (2017), compared with a mean of $2.7 million.
  • Biggest five-year swings in Current Deferred Revenue: crashed 98.36% in 2014 and later skyrocketed 1663.96% in 2016.
  • Neurocrine Biosciences' Current Deferred Revenue stood at $3.3 million in 2014, then surged by 206.86% to $10.2 million in 2015, then crashed by 95.39% to $470000.0 in 2016, then surged by 55.53% to $731000.0 in 2017, then changed by 0.0% to $731000.0 in 2018.
  • The last three reported values for Current Deferred Revenue were $731000.0 (Q1 2018), $731000.0 (Q4 2017), and $3.6 million (Q1 2017) per Business Quant data.